PSC is considered an immune-mediated inflammatory condition; autoimmunity is present in the great majority of affected individuals. No single causative gene is identified in this packet. The precise interplay of immune, environmental, and other factors contributing to biliary inflammation remains under ongoing investigation.

Diagnosis is informed by characteristic hepatobiliary laboratory abnormalities, including elevated alkaline phosphatase and elevated hepatic transaminases. Biliary tract abnormalities and co-occurring inflammatory bowel disease are frequently identified in affected individuals and contribute to the clinical picture.

No treatments are specifically FDA-approved for PSC. Management addresses complications of cholestasis and progressive liver disease and may involve ongoing surveillance for disease progression and associated complications. A multidisciplinary care team coordinates long-term management. Numerous investigational therapies are in active clinical development.

PSC follows a variable but progressive course. Hepatic fibrosis and cirrhosis may develop over years to decades. The pace and degree of progression differ among affected individuals.

PSC is an active area of clinical investigation. Numerous certified active trial records are present, investigating pharmacologic, procedural, microbiome-based, and other approaches. PSC Partners Seeking A Cure maintains a patient registry supporting research engagement.